Rachel Humphrey (CytomX Therapeutics)

Jun 28, 2018, 10:00 PM – Jun 29, 2018, 1:00 AM

Tigerlabs, 252 Nassau Street, 2nd floor, Princeton, 08542

SVP, Chief Medical Officer, CytomX Therapeutics (NASDAQ:CTMX) discusses her career in biotech.

In-person event

About this event

Rachel has extensive experience in biotech.

•Pharmaceutical executive with extensive experience in Product Development from pre-IND to Phase IV/compound commercialization of small molecules, cytotoxics and biologics in oncology and immuno-oncology.

•Proven success in supervising Product Development strategy and tactics over ~18 years in 4 large pharmaceutical companies and in small biotech and with supervision of the successful development of 2 new molecular entities in oncology (NEXAVAR and YERVOY).

•As Senior Vice President and Head of Immuno-Oncology at AstraZeneca, successfully and swiftly (within 9 months) built a high-performing late-stage Immuno-Oncology department and supervised the initiation of the late stage global development of tremelimumab, MEDI4736 (PD-L1 inhibitor) and the treme/MEDI4736 combination.

•In the roles of Executive Vice President, Chief Medical Officer (Mirati Therapeutics, formerly MethylGene Inc.) and/or VP, Global Development (BMS) successfully managed all aspects of specific asset development including clinical, statistics, operations, regulatory, manufacturing, medical, publications, pre-launch and post-launch activities with a focus on global and regional development, including Asia and Japan.

•Extensive experience interacting internally with finance and research functions, and externally with investors, analysts, scientific leaders and large and small pharma collaborators.

•Extensive experience in-licensing compounds and interfacing, through Alliances, between large and small biotech companies.

•Broad interaction with global regulatory authorities including supervision of IND and NDA documents, ODAC preparation and label negotiations.

•Led improvement of process projects in global development and medical affairs.

•Participated on the leadership team and facilitated exit management following the BMS acquisition of 7Medarex and transition of Mirati Therapeutics from Canada to the US.

CytomX is a clinical-stage biopharmaceutical company with a unique approach to treating cancer. After their IPO, they have a market cap of nearly $1B. 

Check out what happened


  • Rachel Humphrey

    Cytomx Therapeutics

    SVP & Chief Medical Officer



June 28 – 29, 2018
10:00 PM – 1:00 AM UTC


Networking and Food
Fireside Chat


  • David Stengle

    Startup Grind Princeton



  • David Stengle


    Princeton Chapter Founder & Director

  • Stan Berteloot

    Nytro Marketing


  • Michael Szubrowski

    Time is Me


  • David Page

    New Road Media


  • John Snee

    Startup Grind Trenton

    Program Director

Global sponsor

Dell Technologies logo

Dell Technologies


Tigerlabs logo


Comcast Business logo

Comcast Business

About Startup Grind

This is Startup Grind. We are the world’s largest startup community.

Our Mission

To give startups everywhere the education and opportunities they need to build, grow, and scale their companies.

Our Values

We believe in making friends, not contacts. We believe in giving first, not taking. We believe in helping others before helping yourself.

Tools & Discounts for Startups

Take advantage of resources and offers provided by organizations we know and love, designed to help you navigate the startup journey.

Global Conference

Our annual flagship event in Silicon Valley brings together thousands of startup teams, investors and organizations from all over the world.

Join the Startup Membership

This membership gives you free access to networking, events, mentorship, office hours, and other exclusive opportunities curated by Startup Grind HQ.